Quinapril/Hydrochlorothiazide Tablet Shortage: Current FDA Status and Availability Updates

What’s in Shortage

Quinapril/Hydrochlorothiazide tablets, a medication used in the Cardiovascular therapeutic category, are currently listed in a shortage status by the FDA. This affects the generic version as well as the brand name QUINAPRIL AND HYDROCHLOROTHIAZIDE.

• Current Status: Current Shortage
• Dosage Form: Tablet
• Initial Posting Date: 01/19/2023
• Last Updated: 02/02/2026

Which Manufacturers Are Affected

According to the latest data, the following manufacturer is supplying the medication with the following availability status:

• Chartwell Molecular Holdings LLC
  • Status: Available
  • Presentations:
    • Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)
    • Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)
    • Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)
  • Contact Information: 845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com

Why There’s a Shortage

No specific reason for the shortage was provided in the source data.

What Patients Should Do

If you are currently prescribed Quinapril/Hydrochlorothiazide, please consider the following steps:

1. Consult Your Pharmacist: Check with your local pharmacy regarding their current stock levels for your specific dosage.
2. Contact Your Healthcare Provider: Discuss your treatment plan and ask about potential alternatives if your specific dosage becomes difficult to find.
3. Contact the Manufacturer: You may reach out to Chartwell Molecular Holdings LLC at the contact information provided above for updates on supply.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should always consult with their healthcare provider or pharmacist regarding their medications and treatment options.

Source

Information provided by the FDA Drug Shortage Database.